--- title: "法隆公司的 Bexmarilimab 數據已被接受，將在 2026 年 BSH 年度科學會議上進行海報展示" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276573595.md" description: "Faron Pharmaceuticals Ltd. 宣佈，其關於 bexmarilimab 與 azacitidine 聯合治療高風險骨髓增生異常綜合症 (MDS) 的 I/II 期 BEXMAB 試驗數據已被接受在 2026 年 4 月舉行的英國血液學會第 66 屆年會進行海報展示。此次展示將包括試驗的最新結果，支持 bexmarilimab 進入下一個開發階段。該公司旨在與血液學界進行交流，並分享該治療的安全性和有效性見解" datetime: "2026-02-23T07:35:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276573595.md) - [en](https://longbridge.com/en/news/276573595.md) - [zh-HK](https://longbridge.com/zh-HK/news/276573595.md) --- # 法隆公司的 Bexmarilimab 數據已被接受，將在 2026 年 BSH 年度科學會議上進行海報展示 **TURKU, FI / ACCESS Newswire / February 23, 2026 /** Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that data from its Phase I/II BEXMAB trial evaluating _bexmarilimab_ in combination with _azacitidine_ for the treatment of higher-risk myelodysplastic syndromes (MDS) have been accepted for presentation at the 66th Annual Scientific Meeting of the British Society for Haematology (BSH), taking place 19-21 April 2026 in Liverpool, UK. The abstract, titled "Bexmarilimab Plus Azacitidine in Higher Risk Myelodysplastic Syndrome: Updated Results from the BEXMAB Study," has been selected for poster presentation (Poster P02.10) under the theme _Myeloid Malignancies and Bone Marrow Failure Syndromes_ . The acceptance supports Faron's consistent scientific presence at major hematology and oncology meetings. While the BSH poster contains updated figures from the latest data cut, the dataset itself is previously reported. Inclusion at BSH underscores the Company's ongoing engagement with the MDS community and its commitment to transparent, continuous reporting of BEXMAB clinical progress. The poster presents the full dataset included in the accepted abstract based on the 3 November 2025 data cut (55 patients: 21 treatment‑naïve; 34 HMA‑refractory/relapsed). The results support the planned advancement of _bexmarilimab_ into the next development phase in treatment‑naïve higher‑risk MDS. **Dr Emma Searle, presenting author from The Christie NHS Foundation Trust and the University of Manchester** , commented: "We are pleased to share the BEXMAB data with the hematology community at BSH. The combination of _bexmarilimab_ and _azacitidine_ continues to show a favorable safety profile and encouraging response rates across both treatment‑naïve and HMA‑refractory higher‑risk MDS populations. Presenting this data at BSH offers a valuable opportunity to engage with investigators and KOLs who are eager for _bexmarilimab_ 's next HR‑MDS trial, exchange clinical insights, and help shape the field's continued progress." **About** _**bexmarilimab**_ _Bexmarilimab_ is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments by targeting Clever-1, a receptor on immunosuppressive macrophages and malignant blasts. By inhibiting Clever-1, _bexmarilimab_ reprograms the tumor microenvironment to ignite a potent anti-tumor immune response. **About BEXMAB** The BEXMAB study is an open-label Phase I/II clinical trial investigating _bexmarilimab_ in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of _bexmarilimab_ in combination with SoC (azacitidine) treatment. **About Faron Pharmaceuticals Ltd.** Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient's own immune system. The Company's lead asset _bexmarilimab_ is currently being investigated in multiple clinical trials as a potential therapy for patients with hematological malignancies and solid tumors in combination with other standard treatments. **For more information, please contact:** **IR Partners, Finland** **(Media)** **Kare Laukkanen** **+358 50 553 9535 / +44 7 469 766 223** **kare.laukkanen@irpartners.fi** **FINN Partners, US** **(Media)** **Alyssa Paldo** **+1 847 791-8085** **alyssa.paldo@finnpartners.com** **Cairn Financial Advisers LLP** **(Nominated Adviser and Broker)** **Sandy Jamieson, Jo Turner** **+44 (0) 207 213 0880** **Sisu Partners Oy** **(Certified Adviser on Nasdaq First North)** **Juha Karttunen** **Jukka Järvelä** **+358 (0) 40 555 4727** **+358 (0) 50 553 8990** **Forward-Looking Statements** This press release contains certain forward-looking statements relating to the business of Faron Pharmaceuticals. In addition, even if the actual results or development of Faron Pharmaceuticals are consistent with the forward-looking statements contained in this press release, those results or developments of Faron Pharmaceuticals may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Faron Pharmaceuticals as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Faron Pharmaceuticals could be affected by, among other things, uncertainties and delays involved in the development of product candidates, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, inflation, changes in tariff policies, political or macroeconomic developments, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Faron Pharmaceuticals is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. **SOURCE:** Faron Pharmaceuticals View the original press release on ACCESS Newswire ### 相關股票 - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [AFP.AU](https://longbridge.com/zh-HK/quote/AFP.AU.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [FBRX.US](https://longbridge.com/zh-HK/quote/FBRX.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [IXJ.AU](https://longbridge.com/zh-HK/quote/IXJ.AU.md) - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [VRTX.US](https://longbridge.com/zh-HK/quote/VRTX.US.md) ## 相關資訊與研究 - [巨生醫細胞治療產品獲 SelectUSA Tech 醫療領域前 8 強 有助美國市場佈局](https://longbridge.com/zh-HK/news/282988767.md) - [藥廠 AI 合作潮！諾和諾德攜手 OpenAI 股價走揚](https://longbridge.com/zh-HK/news/282755292.md) - [巨生醫細胞治療產品 MPB-2354 獲選 SelectUSA Tech 醫療領域前八強](https://longbridge.com/zh-HK/news/282972944.md) - [Korro Bio 將在 ASGCT 會議上展示 KRRO-121 治療高氨血癥的臨牀前數據](https://longbridge.com/zh-HK/news/282990992.md) - [Acurx Pharmaceuticals 以 250 萬美元定價進行註冊直接發行，並同時附帶認股權證](https://longbridge.com/zh-HK/news/282999879.md)